Ganaxolone for use in treating tuberous sclerosis complex and seizure disorders
AssigneeMarinus Pharmaceuticals
InventorsJoseph HULIHAN, Alex AIMETTI, Scott BRAUNSTEIN
Life of this patent
Estimating the term…
Abstract
The disclosure to methods for treating tuberous sclerosis complex and epilepsy disorders comprising administering to a subject in need thereof a therapeutically effective amount of ganaxolone or a pharmaceutically acceptable salt thereof.
Claims38
A method for treating seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder, comprising orally administering to a subject in need thereof ganaxolone in an amount of:
- about 150 mg per day for about one week, followed by about 300 mg per day for about one week, followed by about 600 mg per day for about one week, followed by about 1,200 mg per day for about one week, followed by about up to 1,800 mg per day for the remaining treatment period.
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method for treating seizures associated with CDKL5 deficiency disorder, comprising orally administering to a subject in need thereof ganaxolone in an amount of:
- about 6 mg/kg/day for about one week, followed by about 12 mg/kg/day for about one week, followed by about 24 mg/kg/day for about one week, followed by about 42 mg/kg/day for about one week, followed by about up to 63 mg/kg/day for the remaining treatment period.
21-26. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
38-76. (canceled)
Dependencies are inferred from the claim text.